DENTSPLY SIRONA (NASDAQ:XRAY) Director Acquires $101,200.00 in Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Brian Mckeon bought 10,000 shares of the company’s stock in a transaction on Friday, June 12th. The stock was purchased at an average price of $10.12 per share, with a total value of $101,200.00. Following the completion of the transaction, the director directly owned 10,000 shares of the company’s stock, valued at approximately $101,200. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

DENTSPLY SIRONA Price Performance

DENTSPLY SIRONA stock opened at $10.03 on Thursday. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52. The company has a market capitalization of $2.01 billion, a PE ratio of -3.18, a P/E/G ratio of 1.24 and a beta of 0.89. DENTSPLY SIRONA Inc. has a 12 month low of $9.40 and a 12 month high of $17.09. The stock has a 50-day moving average price of $10.90 and a two-hundred day moving average price of $11.69.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The firm had revenue of $880.00 million during the quarter, compared to the consensus estimate of $841.80 million. During the same quarter in the prior year, the business posted $0.43 earnings per share. DENTSPLY SIRONA’s revenue for the quarter was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Analysts expect that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on XRAY. Citigroup began coverage on DENTSPLY SIRONA in a research report on Wednesday, April 15th. They set a “sell” rating and a $10.00 price objective for the company. Zacks Research upgraded DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Robert W. Baird raised their price objective on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, February 27th. UBS Group lowered their price objective on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Mizuho lowered their target price on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Three investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $13.55.

Institutional Investors Weigh In On DENTSPLY SIRONA

Hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of DENTSPLY SIRONA during the first quarter valued at approximately $26,000. Goldman Sachs Group Inc. boosted its position in shares of DENTSPLY SIRONA by 827.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after buying an additional 2,172,343 shares during the last quarter. Empowered Funds LLC boosted its position in shares of DENTSPLY SIRONA by 8.8% during the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after buying an additional 1,320 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of DENTSPLY SIRONA by 7.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after buying an additional 41,579 shares during the last quarter. Finally, Focus Partners Wealth boosted its position in shares of DENTSPLY SIRONA by 59.1% during the first quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after buying an additional 9,355 shares during the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.